EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE 
EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE
Myeloma Patients Europe will be present at the 56th American Society of Hematology Annual Meeting, to be held in San Francisco betweeb 6 and 9 December. Over 20.000 people from all arround the globe will attend the largest hematology event in the world. Hundreds of sessions, posters and exhibits will bring together, not only hematologists, but also other stakeholders, such as non-clinical researchers, nurses, industry and, of course, patients.
For yet another year, Myeloma Patients Europe will be present at the European Society for Medical Oncology Congress. The event will take place in Madrid between the 26 to 30 of September. The main congress of European Oncology is expected to meet over 16.000 attendees from over 120 countries. ESMO 2014 intends to merge state-of-the-art oncology with the latest breakthrough discoveries, from cost-effective anti-cancer treatments to best supportive care.
The MPE Member Update is a bi-monthly summary of the activities undertaken by MPE members. It inlcudes updates on the projects and activities they have been involved in over the last two month and their plans for the nearer future. The September issue of the MPE Member Update has just been published. To check the updates by member group, please click here. If you wish to subscribe to the MPE Member Update or the MPE…
We are delighted to anounce that the MPE report on Myeloma Patient Perspectives is being launched today, Friday 14 June 2013. Printed copies are available at EHA 2013 in Stockholm. Please feel free to pick up a copy at the EHA MPE booth (table top C14:11) from 14-16 June 2013. For more information on these report, please send an email to
MPE will be represented by several delegates at the 18th EHA congress in Stockholm (13-16 June 2013). We also have a booth where printed versions of our key documents and recent publications will be provided, such as the MPE report on Myeloma Patient Perspectives, the executive summary of the report, a summary of our strategic plan 2013-2018 and the Clinical Trial Charter developed by MPE.
